AARTIDRUGS · NSE
Aarti Drugs Limited
₹431.8
+0.81% (+₹3.45)
Prev. close
₹428.35
Volume
88,332
Delivery %
55.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzenesulphonyl chloride, benzenesulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Prakash Moreshwar Patil
Headquarters
Mumbai
Employees
1,355
Website
aartidrugs.co.inExchange
View on NSE ↗Key stats
Market cap
₹3,941.04 Cr
P/E ratio (TTM)
20.6
Dividend yield
0.47%
EPS (TTM)
₹20.95
Beta (1Y · daily vs NIFTY 50)
0.88
Beta (5Y · monthly vs NIFTY 50)
1.05
Shares float
3.54 Cr
EPS · quarter ended Jun 2026
₹5.49
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.4% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,154.78 Cr | ₹2,488.65 Cr | ₹2,716.05 Cr | ₹2,528.58 Cr | ₹2,387.03 Cr | ₹2,565.31 Cr | |
| EBITDA | ₹441.85 Cr | ₹340.76 Cr | ₹307.79 Cr | ₹320.50 Cr | ₹303.42 Cr | ₹311.58 Cr |
| ₹280.00 Cr | ₹205.00 Cr | ₹166.31 Cr | ₹171.42 Cr | ₹168.16 Cr | ₹194.92 Cr | |
| Diluted EPS | ₹30.09 | ₹22.12 | ₹17.97 | ₹18.56 | ₹18.35 | ₹21.36 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,766.00 Cr | ₹2,207.96 Cr | ₹2,421.00 Cr | ₹2,432.00 Cr | ₹2,575.00 Cr | ₹2,815.00 Cr | |
| — | ₹542.82 Cr | ₹608.91 Cr | ₹564.28 Cr | ₹615.07 Cr | ₹576.63 Cr | |
| Stockholders' equity | ₹913.00 Cr | ₹1,036.36 Cr | ₹1,193.00 Cr | ₹1,282.00 Cr | ₹1,369.00 Cr | ₹1,549.00 Cr |
Current assets, Inventory, Receivables (trade + unbilled), Trade receivables, Unbilled receivables (contract assets), Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹154.84 Cr | ₹69.64 Cr | ₹133.00 Cr | ₹359.00 Cr | ₹245.00 Cr | ₹254.00 Cr | |
| Investing cash flow | ₹-71.68 Cr | ₹-148.86 Cr | ₹-163.97 Cr | ₹-223.65 Cr | ₹-164.63 Cr | ₹-173.41 Cr |
| ₹-81.12 Cr | ₹92.02 Cr | ₹17.00 Cr | ₹-136.00 Cr | ₹-82.00 Cr | ₹-77.00 Cr | |
| Capital expenditure | ₹-88.13 Cr | ₹-143.68 Cr | ₹-164.67 Cr | ₹-226.33 Cr | ₹-177.16 Cr | ₹-173.32 Cr |
| End cash position | ₹8.81 Cr | ₹22.33 Cr | ₹8.38 Cr | ₹6.74 Cr | ₹4.57 Cr | ₹7.27 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25–Mar 26(2Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 60.12% | 59.99% | 59.83% | 59.98% | 59.77% | 59.66% | 59.58% | 58.70% | 58.56% | 57.47% | 57.13% | 55.67% | 55.64% | 55.38% | 55.48% | 55.22% | 54.72% | 55.03% | 54.43% |
| Public | 39.88% | 40.01% | 40.17% | 40.02% | 40.23% | 40.34% | 40.42% | 41.30% | 41.44% | 42.53% | 42.87% | 44.33% | 44.36% | 44.62% | 44.52% | 44.78% | 45.28% | 44.97% | 45.57% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aarti Drugs Limited | ₹3,872.59 Cr | ₹428.35 | 20.3 | 2.50 | 12.6% | 0.37 | +6.4% | -16.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
10 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Pharma sector stocks fall today, September 16: Aarti Drugs down 2.30%, Natco Pharma declines 2%, Glenmark Pharma falls 1.47%
Business Upturn · 3 days ago
Pharma sector stocks down today, September 2: Aarti Drugs falls 1.90%, Cipla down 1.18%, Panacea Biotec drops 0.73%
Aarti Drugs shares fell 1.90% on the NSE and 2.16% on the BSE during Wednesday's morning session. This decline occurred as many Indian pharmaceutical stocks traded lower, contributing to a broader downturn in the equity market. The S&P BSE Healthcare index also slipped 0.24%.